Logo
  • Careers
  • Contact Us
  • Donate
  • Subscribe
Search
  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
      • HIV Vaccine Translational Research Laboratory
      • Human Immunology Laboratory
      • IAVI Neutralizing Antibody Center
      • Vaccine Design and Development Laboratory
    • Translation & Product Development
    • Clinical & Epidemiology Research
      • ADVANCE
      • Clinical Research Centers
      • Clinical Research Standards
      • HIV Epidemiology
    • Global Community Engagement
      • Africa Program
      • CASPR
      • End-User Research
      • World Bank/Japan-supported
        Partnerships | 日本政府・世銀が支援するパートナーシップ
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
  • Careers
  • Contact Us
  • Donate
  • Subscribe

Search

  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
    • Translation & Product Development
    • Clinical & Epidemiology Research
    • Global Community Engagement
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
COVID-19
  • Latest NewsLatest News
  • Scientific Publications Scientific Publications
  • Press Releases
  • Features
  • IAVI Report
  • IAVI in the News
  • Fact Sheets & Publications
  • VOICES Newsletter
  • Media Contacts
  • Subscribe

Scientific Publications

Filter By:

 

 
Filters

Kiwuwa-Muyingo S, Nazziwa J, Ssemwanga D, Ilmonen P, Njai H, Ndembi N, Parry C, Kitandwe PK, Gershim A, Mpendo J, Neilsen L, Seeley J, Seppälä H, Lyagoba F, Kamali A, Kaleebu P

HIV-1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda: A phylogenetic and epidemiological approach. PLoS ONE 2017;12(10):e0185818 doi: 10.1371/journal.pone.0185818

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Fishing communities around Lake Victoria in sub-Saharan Africa have been characterised as a population at high risk of HIV-infection.

Topics: HIV Transmission

Keywords: Fishing Communities

Safrit JT, Fast PE, Gieber L, Kuipers H, Dean HJ, Koff WCStatus of vaccine research and development of vaccines for HIV-1. Vaccine 2016;34(26):2921-2925 doi: S0264-410X(16)00280-2

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Human immunodeficiency virus (HIV) is the cause of one of the most lethal pandemics in human history, although in recent years access to highly effective anti-retroviral therapy has provided new hope worldwide. Transmission of HIV by sexual contact, childbirth and injection drug use has been reduced, but 2 million are newly infected each year, and much of the transmission is from people who do not know their status. In addition to known methods, a preventive vaccine is needed to end the pandemic. The extraordinary mutability and genetic diversity of HIV is an enormous challenge, but vaccines are being designed for broad coverage. Computer-aided design of mosaic immunogens, incorporating many epitopes from the entire genome or from conserved regions aim to induce CD8+ T cells to kill virus-infected cells or inhibit virus replication, while trimeric envelope proteins or synthetic mimics aim to induce broadly reactive neutralizing antibodies similar to those cloned from some infected patients. Induction of more potent and durable responses may require new adjuvants or replicating chimeric vectors chimeras that bear HIV genes. Passive or genetic delivery of broadly neutralizing antibodies may provide broad protection and/or lead to insights for vaccine designers. Proof-of-concept trials in non-human primates and in one human efficacy trial have provided scientific clues for a vaccine that could provide broad and durable protection against HIV. The use of vaccines to destroy HIV reservoirs as part of therapy or cure is now also being explored.

Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DRGlycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. Immunity 2017;47(3):524-537.e3 doi: S1074-7613(17)30364-3

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Apex broadly neutralizing HIV antibodies (bnAbs) recognize glycans and protein surface close to the 3-fold axis of the envelope (Env) trimer and are among the most potent and broad Abs described. The evolution of apex bnAbs from one donor (CAP256) has been studied in detail and many Abs at different stages of maturation have been described. Using diverse engineering tools, we investigated the involvement of glycan recognition in the development of the CAP256.VRC26 Ab lineage. We found that sialic acid-bearing glycans were recognized by germline-encoded and somatically mutated residues on the Ab heavy chain. This recognition provided an 'anchor' for the Abs as the core protein epitope varies, prevented complete neutralization escape, and eventually led to broadening of the response. These findings illustrate how glycan-specific maturation enables a human Ab to cope with pathogen escape mechanisms and will aid in optimization of immunization strategies to induce V2 apex bnAb responses.

Nyaoke BA, Mutua GN, Sajabi R, Nyasani D, Mureithi MW, Anzala OA

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya. PLoS ONE 2017;12(9):e0183788 doi: 10.1371/journal.pone.0183788

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

1.5 million Kenyans are living with HIV/AIDS as per 2015 estimates. Though there is a notable decline in new HIV infections, continued effort is still needed to develop an efficacious, accessible and affordable HIV vaccine. HIV vaccine clinical trials bear risks, hence a need to understand volunteer motivators for enrolment, retention and follow-up. Understanding the factors that motivate volunteers to participate in a clinical trial can help to strategize, refine targeting and thus increase enrolment of volunteers in future HIV vaccine clinical trials. The health belief model classifies motivators into social benefits such as 'advancing research' and collaboration with science, and personal benefits such as health benefits and financial interests.

Topics: Capacity Building and Research Preparedness

Kumar R, Ozorowski G, Kumar V, Holden LG, Shrivastava T, Patil S, Deshpande S, Ward AB, Bhattacharya JCharacterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. J. Biol. Chem. 2017;292(38):15849-15858 doi: 10.1074/jbc.M117.803056

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

The HIV-1 envelope (Env) is a glycoprotein consisting of a trimer of heterodimers containing gp120 and gp41 subunits that mediates virus entry and is a major target of broadly neutralizing antibodies (bnAbs) developed during infection in some individuals. The engagement of the HIV-1 gp120 glycoprotein to the host CD4 protein triggers conformational changes in gp120 that allow its binding to co-receptors and is necessary for virus entry to establish infection. Native-like HIV-1 Env immunogens representing distinct clades have been proposed to improve immunogenicity. In the present study, we examined the basis of resistance of an HIV-1 B/C recombinant Env (LT5.J4b12C) to non-neutralizing antibodies targeting CD4-induced Env epitopes in the presence of soluble CD4 (sCD4). Using native polyacrylamide gel shift assay and negative-stain EM, we found that the prefusion conformational state of LT5.J4b12C trimeric Env was largely unaffected in the presence of excess sCD4 with most Env trimers appearing to be in a ligand-free state. This resistance to CD4-induced conformational changes was associated with a lower affinity for CD4. Moreover, the LT5.J4b12C trimeric Env preferentially bound to the neutralizing antibodies compared with non-neutralizing antibodies. Taken together, we report on an HIV-1 B/C recombinant, native-like trimeric Env protein that is highly resistant to CD4-induced conformational changes but displays epitopes recognized by a diverse array of bnAbs. Such features make this B/C recombinant trimeric Env a useful addition to the pool of other recently identified native-like HIV-1 Env trimers suitable for use as antigenic bait for bnAb isolation, structural studies, and use as potential immunogens.

Murray SE, Nesterenko PA, Vanarsdall AL, Munks MW, Smart SM, Veziroglu EM, Sagario LC, Lee R, Claas FHJ, Doxiadis IIN, McVoy MA, Adler SP, Hill ABFibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans. J. Exp. Med. 2017;214(7):1889-1899 doi: 10.1084/jem.20161988

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Cytomegalovirus (CMV)-based vaccines have shown remarkable efficacy in the rhesus macaque model of acquired immune deficiency syndrome, enabling 50% of vaccinated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge. The protective vaccine elicited unconventional CD8 T cell responses that were entirely restricted by MHC II or the nonclassical MHC I molecule, MHC-E. These unconventional responses were only elicited by a fibroblast-adapted rhesus CMV vector with limited tissue tropism; a repaired vector with normal tropism elicited conventional responses. Testing whether these unusual protective CD8 T responses could be elicited in humans requires vaccinating human subjects with a fibroblast-adapted mutant of human CMV (HCMV). In this study, we describe the CD8 T cell responses of human subjects vaccinated with two fibroblast-adapted HCMV vaccines. Most responses were identified as conventional classically MHC I restricted, and we found no evidence for MHC II or HLA-E restriction. These results indicate that fibroblast adaptation alone is unlikely to explain the unconventional responses observed in macaques.

Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse PJ, Sanders RW, Moore JP, Hanke THIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE 2017;12(8):e0181886 doi: 10.1371/journal.pone.0181886

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Rabbits and monkeys immunized with HIV type 1 (HIV-1) native-like BG505 SOSIP.664 (BG505s) glycoprotein trimers are known to induce antibodies that can neutralize the autologous tier-2 virus. Here, we assessed the induction of HIV-1 trimer binding and neutralizing antibody (nAb) titres when BG505s trimers were also delivered by non-replicating simian (chimpanzee) adenovirus and non-replicating poxvirus modified vaccinia virus Ankara (MVA) vaccine vectors. First, we showed that approximately two-thirds and one-third of the trimers secreted from the ChAdOx1.BG505s (C) and MVA.BG505s (M) vaccine-infected cells, respectively, were cleaved and in a native-like conformation. Rabbits were immunized intramuscularly with these vaccine vectors and in some cases boosted with ISCOMATRIX™-adjuvanted BG505s protein trimer (P), using CCC, MMM, PPP, CPP, MPP and CMP vaccine regimens. We found that the peak trimer-binding antibody and tier-1A and autologous tier-2 nAb responses induced by the CC, CM, PPP, CPP, MPP and CMP regimens were comparable, although only PPP induced autologous tier-2 nAbs in all the immunized animals. Three animals developed weak heterologous tier-2 nAbs. These results demonstrate that ChAdOx1 and MVA vectors are useful delivery modalities for not only T-cell, but also antibody vaccine development.

Mabuka JM, Dugast AS, Muema DM, Reddy T, Ramlakhan Y, Euler Z, Ismail N, Moodley A, Dong KL, Morris L, Walker BD, Alter G, Ndung'u T

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front Immunol 2017;8:1104 doi: 10.3389/fimmu.2017.01104

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Immunological events in acute HIV-1 infection before peak viremia (hyperacute phase) may contribute to the development of broadly cross-neutralizing antibodies. Here, we used pre-infection and acute-infection peripheral blood mononuclear cells and plasma samples from 22 women, including 10 who initiated antiretroviral treatment in Fiebig stages I-V of acute infection to study B cell subsets and B-cell associated cytokines (BAFF and CXCL13) kinetics for up to ~90 days post detection of plasma viremia. Frequencies of B cell subsets were defined by flow cytometry while plasma cytokine levels were measured by ELISA. We observed a rapid but transient increase in exhausted tissue-like memory, activated memory, and plasmablast B cells accompanied by decline in resting memory cells in untreated, but not treated women. B cell subset frequencies in untreated women positively correlated with viral loads but did not predict emergence of cross-neutralizing antibodies measured 12 months post detection of plasma viremia. Plasma BAFF and CXCL13 levels increased only in untreated women, but their levels did not correlate with viral loads. Importantly, early CXCL13 but not BAFF levels predicted the later emergence of detectable cross-neutralizing antibodies at 12 months post detection of plasma viremia. Thus, hyperacute HIV-1 infection is associated with B cell subset changes, which do not predict emergence of cross-neutralizing antibodies. However, plasma CXCL13 levels during hyperacute infection predicted the subsequent emergence of cross-neutralizing antibodies, providing a potential biomarker for the evaluation of vaccines designed to elicit cross-neutralizing activity or for natural infection studies to explore mechanisms underlying development of neutralizing antibodies.

Topics: HIV Acute Infection, HIV Neutralizing Antibodies

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RWDesign and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 2017;214(9):2573-2590 doi: 10.1084/jem.20161160

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective vaccine. A critical step in this process is the activation of naive B cells expressing germline (gl) antibody precursors that have the potential to evolve into bNAbs. Here, we reengineered the BG505 SOSIP.664 glycoprotein to engage gl precursors of bNAbs that target either the trimer apex or the CD4-binding site. The resulting BG505 SOSIP.v4.1-GT1 trimer binds multiple bNAb gl precursors in vitro. Immunization experiments in knock-in mice expressing gl-VRC01 or gl-PGT121 show that this trimer activates B cells in vivo, resulting in the secretion of specific antibodies into the sera. A crystal structure of the gl-targeting trimer at 3.2-Å resolution in complex with neutralizing antibodies 35O22 and 9H+109L reveals a native-like conformation and the successful incorporation of design features associated with binding of multiple gl-bNAb precursors.

Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JPSequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathog. 2016;12(9):e1005864 doi: 10.1371/journal.ppat.1005864

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

We have investigated the immunogenicity in rabbits of native-like, soluble, recombinant SOSIP.664 trimers based on the env genes of four isolates of human immunodeficiency virus type 1 (HIV-1); specifically BG505 (clade A), B41 (clade B), CZA97 (clade C) and DU422 (clade C). The various trimers were delivered either simultaneously (as a mixture of clade A + B trimers) or sequentially over a 73-week period. Autologous, Tier-2 neutralizing antibody (NAb) responses were generated to the clade A and clade B trimers in the bivalent mixture. When delivered as boosting immunogens to rabbits immunized with the clade A and/or clade B trimers, the clade C trimers also generated autologous Tier-2 NAb responses, the CZA97 trimers doing so more strongly and consistently than the DU422 trimers. The clade C trimers also cross-boosted the pre-existing NAb responses to clade A and B trimers. We observed heterologous Tier-2 NAb responses albeit inconsistently, and with limited overall breath. However, cross-neutralization of the clade A BG505.T332N virus was consistently observed in rabbits immunized only with clade B trimers and then boosted with clade C trimers. The autologous NAbs induced by the BG505, B41 and CZA97 trimers predominantly recognized specific holes in the glycan shields of the cognate virus. The shared location of some of these holes may account for the observed cross-boosting effects and the heterologous neutralization of the BG505.T332N virus. These findings will guide the design of further experiments to determine whether and how multiple Env trimers can together induce more broadly neutralizing antibody responses.

Page 13 of 87

StartPrev8...1011121314...1617NextEnd

About

About

Board of Directors

Senior Leadership

Financial Statements

Global Funding & Support

Our Work

Our Work

Discovery

Translation & Product Development

Clinical & Epidemiology Research

Global Community Engagement

IAVI DataSpace

Our Science

Our Science

Pipeline

HIV Vaccines

bnAbs for HIV Prevention

Tuberculosis Vaccines

Emerging Infectious Diseases Vaccines and Therapeutics

Snakebite

News & Resources

Latest NewsLatest News

Scientific Publications Scientific Publications

Press Releases

Features

IAVI Report

IAVI in the News

Fact Sheets & Publications

VOICES Newsletter

Media Contacts

Subscribe

icon charity navigator icon guide star icon iavi

Accessibility

Compliance

Contact IAVI

Privacy Policy

Site Map

Supplier Diversity

Terms of Use

©2021 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.